about
Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillationHSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced atrial myocytesRationale and current perspective for early rhythm control therapy in atrial fibrillation.Troponin I isoform expression in human and experimental atrial fibrillationCyclical stretch induces structural changes in atrial myocytesScreening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration.Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins.Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation).Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies.Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study.Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND study.Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm AssociGender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study.Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study.Lone atrial fibrillation: does it exist?Relation of overweight and symptomatic atrial fibrillation: A case report.Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study.The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study.An entirely subcutaneous implantable cardioverter-defibrillator.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Molecular mechanisms of remodeling in human atrial fibrillation.How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation.Atrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload.The RACE study in perspective of randomized studies on management of persistent atrial fibrillation.Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointesSymptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.Genetic aspects of atrial fibrillation.Cluster Individuals Based on Phenotype and Determine the Risk for Atrial Fibrillation in the PREVEND and Framingham Heart Study Populations.Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation.The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm.Who, when and how to rate control for atrial fibrillation.New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'.Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.Upstream therapy of atrial fibrillation.Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation.New treatment options for atrial fibrillation: towards patient tailored therapy.
P50
Q24801156-28876732-2B23-4238-8075-8E15B2139444Q27339155-B2E34593-5781-411A-9188-489EDB690EACQ27692632-6AE5F494-403F-4A3D-AB6D-D84D27AD9E69Q28275264-CBB05140-526F-4C4E-9595-06CC2D8ECD5FQ28570323-DF373834-65E4-447C-B005-50D021750FE4Q30234524-785478C2-D8AA-439F-BEF0-4D2336F40969Q30241128-6BC9F0AD-4FE5-4867-B466-FA20B8785192Q30588773-10400DBB-A8FF-442E-B922-888E033C9F10Q30663685-0029D8BF-B4FE-447C-B43A-DE5DED073408Q30830811-2B0C3498-40D7-4882-AE07-5ED16C4D0D32Q31061099-CFFEAACC-3B86-4203-9577-1DC6ECF3B303Q31097352-5FFA32B3-31C5-4C48-A18D-2C32B4F78DE1Q31160340-9A75FC4C-52C0-4728-A746-6018834E003DQ33156522-96E40867-1BDB-4BB7-8BEA-8831DB9818E7Q33162947-573983E9-C784-4698-BB56-3BF75C4D8CE1Q33224413-37A5EF62-B527-4DC4-AB68-CE9B4A7DCB49Q33512193-2F456239-C259-4860-9D4C-962B32EFEB0EQ33560948-56F568C6-D38E-42AE-9469-98BFCF8B1CC8Q33643412-EEBB53D0-1EA7-4CF4-908C-9656F1A4578AQ33996360-680DB689-14C2-44F7-B318-00A74D82FFB1Q34047722-4B09E470-1FFD-4E91-9884-43630783874EQ34114976-A6C72D94-E3E0-444B-82F9-05F686424D22Q34538645-B14664FC-5BD7-40FD-83DF-32CF2DEE8CB5Q34682996-50BFACAF-8A05-4AE6-8B41-30CFCDE49491Q34814706-29CA37CA-69D9-4061-B19F-DD0F37D33F0AQ34988512-A06EE4B7-1CCB-4B66-88CA-BAC30FC976AFQ35583930-6411EDE1-FD63-4D33-BE91-78F3677829D7Q35609742-82B1BEBB-0E80-4169-B069-97B99BA16FA3Q35783016-E6327DF1-2AF8-42D5-8F3E-833F297AF99FQ36108848-8F3C75F1-9840-40BD-BBEC-0CF546B19303Q36142161-9F353212-FF92-4F05-BACA-860D8F68496CQ36188656-809DDD44-622B-4F9B-91C2-CE8A4C917BD6Q36307029-17EACE47-7B9F-4ABF-89B9-9BE96AA86C15Q36594486-55A92D78-4D9F-417D-A43C-DC75DE75E95FQ37087180-DA8A9ED7-1FC6-49D8-9D38-EACC5A7C2FE6Q37163753-C27F2AC8-D588-4DC1-9B69-C4313F9632E3Q37222352-35D9193D-FEB1-484C-AEFF-24C0B5CAB55CQ37546133-350CF669-0377-4F25-9F52-90A377121457Q37809401-5625FCE1-AB7D-422E-BBA0-325BA4B3E721Q37943749-A5897FE2-5186-4613-BAE6-023D275D5752
P50
name
Isabelle C Van Gelder
@en
Isabelle C Van Gelder
@nl
type
label
Isabelle C Van Gelder
@en
Isabelle C Van Gelder
@nl
prefLabel
Isabelle C Van Gelder
@en
Isabelle C Van Gelder
@nl